Navigation Links
CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
Date:1/19/2008

ATLANTA, Jan. 20 /PRNewswire/ -- CeloNova BioSciences, Inc. ("CeloNova"), leading and accelerating healthcare solutions through the development of innovative medical devices, today announced breakthrough results from the ATLANTA study of the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F at the 20th Annual International Symposium on Endovascular Therapy (ISET).

(Photo: http://www.newscom.com/cgi-bin/prnh/20080120/CLSU002 )

Corrado Tamburino, MD, President of the Italian Society of Interventional Cardiology, Chief of Interventional Cardiology at Ferrarotto Hospital and Full Professor of Cardiology at the University of Catania is Principal Investigator for the ATLANTA study. Dr. Tamburino noted, "I perform many angioplasties in each single day, many, and I am totally impressed by the performance of this stent in a very complex patient population. No thrombosis. Low binary restenosis. No MIs. This may be an answer to the problems we are facing with other stent systems."

The CATANIA(TM) Stent System with NanoThin Polyzene(R)-F, dubbed "The CAT" by cardiologists who have used the product, has completed CE Marking and is available for sale anywhere the CE Mark is accepted. Advantages include:

-- Early and complete vessel healing, as early as 30 days.

-- Patients can discontinue dual anti-platelet therapy after only one

month.

-- Protection from stent thrombosis

-- The Polyzene(R)-F surface treatment is bacterial-resistant

"The FDA has cautioned physicians about a small but significant increased risk of stent thrombosis for patients with drug-eluting stents. Now, Britain's National Institute for Health and Clinical Excellence is considering restrictions on DES because they are not cost-effective for most patients and because of uncertainties about safety. Polyzene(R)-F seems to solicit a positive biologic
'/>"/>

SOURCE CeloNova BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
11. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... -- Investor-Edge has initiated coverage on the following ... and Company (NYSE: LLY ), Nektar Therapeutics (NASDAQ: ... and Novartis AG (NYSE: NVS ). Free research ... . On Friday, December 12, 2014, the NASDAQ ... Average lost 1.79%, to finish the day at 17,280.83, and ...
(Date:12/15/2014)... , December 15, 2014 ... development company, is pleased to announce the grant of ... relating to its GPCR-focused drug discovery platform. ... strengthens the global patent estate covering Heptares, technologies and ... suite of patents recently granted by the US Patent ...
(Date:12/13/2014)... HUNTSVILLE, Ala. , Dec. 12, 2014 /PRNewswire-USNewswire/ ... has purchased the HiSeq X Ten sequencing system ... will enable HudsonAlpha to produce and analyze genomic ... purchase stems from the Institute,s commitment to research ... The HiSeq X Ten provides unprecedented capacity, ...
Breaking Medicine Technology:Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 3
(Date:12/15/2014)... 2014 SIMpalm, a leading mobile ... for iPhone for its client, which allows users to ... company, specialized in finding the right wine. At ... uses combined sensory, chemistry and wine information. All this ... “wine fingerprint.” Those wines that are close counterparts to ...
(Date:12/15/2014)... HealthDay Reporter FRIDAY, Dec. 12, ... the millions of American women who have migraine: The debilitating ... is no association between migraine and breast cancer risk," said ... Harvard Medical School. "There is no positive association, so there ... effect either." About 18 percent of American women and ...
(Date:12/15/2014)... SIMSBURY, CT (PRWEB) December 15, 2014 ... in the prestigious Women World Awards in the category ... of a gold award for her weekly career blog ... and practical advice to help professionals elevate their talent ... Her blog, named after her book Networking Ahead ...
(Date:12/15/2014)... CA (PRWEB) December 15, 2014 At ... the organizations AutismOne and Focus Autism ... enlighten attendees with research on the effects of toxins ... testing and intervention information. , Luminaries such as ... researchers from abroad with esteemed, credentialed colleagues of the ...
(Date:12/15/2014)... La Jolla, Calif. (PRWEB) December 15, 2014 ... Roasters made the Coffee Review “Top 30 Coffees of 2014.” ... number two, and their Guji Zone Ethiopia at number 10. ... list twice. , Coffee Review’s selection is ranked on ... The Sumatra Ulos Batak scored 96 out of 100, and ...
Breaking Medicine News(10 mins):Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3Health News:Bird Rock Coffee Roasters Ranks Second and Tenth in Coffee Review’s ‘Top 30 Coffees of 2014’ 2
... clinic, injecting an anesthetic at certain points can reduce the ... is being presented today at the annual meeting of the ... Diego, had found that about 16% of patients encounter a ... was explained that the biopsies are commonly performed on men ...
... a new type of insulin that is inhaled rather ... respiratory infection or are exposed to passive smoke.// ... for treatment of diabetes. It uses an inhaler developed ... for healthcare providers," Professor Philippe Camus of the University ...
... the Queen’s Balmoral Castle in Scotland kills cancer cells and ... the University of Maribor in Slovenia said that they placed ... them to those placed in normal lab water. ,They ... cancer cells 62.5 percent more quickly than normal water. In ...
... nurses will be given ?5,000 to retrain ... Scotland. Health minister Andy Kerr said that ... million over two years on this plan.// ... nurses who are trained outside Europe and ...
... that "any disorder in human faculties" increases dependence on ... Abdul Kalam Wednesday urged researchers to "direct their efforts ... affected by autism".// ,Equality can be generated ... skills and engaging the minds of affected children in ...
... Fatigue is so common among Americans that it almost ... says that although the underlying cause of persistent fatigue ... fatigue is imaginary.// ,According to Boosting Your Energy, ... emotionally. Still, most people—even those being treated for fatigue-producing ...
Cached Medicine News:Health News:Autistic Children Need Sense of Equality: A.P.J. Abdul Kalam 2Health News:Boosting Energy Naturally 2
... an all-original guide prepared specifically ... Derived from "PocketMedicine/Internal Medicine", it ... to those training in the ... who are frequently the first ...
... enable all those involved with healthcare decisions ... very latest evidence in their field of ... each year as the volume of evidence ... delivering the best single source available for ...
... enable all those involved with healthcare decisions ... very latest evidence in their field of ... each year as the volume of evidence ... delivering the best single source available for ...
On the wards, on rounds, or at the bedside, clinicians can instantly access authoritative, up-to-date, practical guidelines for the immediate and long-term medical and surgical management of all card...
Medicine Products: